Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
Browsing: Immune Response
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
Researchers have accurately profiled the immune response to COVID-19 in critically ill patients, allowing them to identify six inflammatory molecules as potential targets for COVID-19 treatment.
Scientists have investigated the genetic variation in immunity against seven viruses including the SARS-COV-2. The results reveal some HLA variants that may provide the most effective immune response to the viruses.
Emerging evidence has suggested that B cells and humoral immunity could modulate the immune response to intracellular pathogens. We speak to Babak Javid about his research on this topic and the importance of learning about immune factors in order to develop vaccination strategies and to understand latent TB.
A mouse study has revealed that obesity may be one factor explaining the significant amount of variation in the influenza virus each year, likely due to an impaired interferon defense response.
A novel study conducted by researchers at Harvard Medical School (MA, USA) has identified how the maternal gut microbiome could protect their newborn children from E. coli infection.
Administering the BCG vaccine intravenously, as opposed to intradermally, could improve the efficacy of the immunization according to new research in macaque models.